Presentation is loading. Please wait.

Presentation is loading. Please wait.

3rd September 2010 INSERM, Lyon

Published byDana Townsend Modified over 7 years ago

Similar presentations

Presentation on theme: "3rd September 2010 INSERM, Lyon"— Presentation transcript:

1 3rd September 2010 INSERM, Lyon The Centre for Emergency Preparedness and Response Translational Research Miles Carroll Director of Research CEPR

2 Health Protection Agency
NIBSC CEPR HPA CfI CRCE RMN/LaRs

3 Developing Interventions: UK & Global Public Health
CEPR: Translational Research Activities Developing Interventions: UK & Global Public Health Safe containment, diagnosis and study of dangerous pathogens Applied research capability including animal facilities Development and production of highly specialised biological products Emergency response capability Working in Partnership with Industry and academia

4 Translational Research
Vaccines Therapeutics Antibiotics/antivirals Immunotherapy Immune modulation Diagnostics Decontamination Developing Interventions for UK Public Health: In Partnership with Industry and Academia

5 An Integrated Capability for the Development of Interventions
Development route is in vitro, in vivo, product development and clinical studies NVEC Discovery Development Licensure Applied research Translational research Working with Partners to develop interventions. Past successes: Whooping cough, Menningitis, Anthrax, Plague, Dysport (cerebral Palsy), Erwinase (childhood leukaemia treatment, Decontamination products

6 Translational Research Model
Industry Vaccine Ags Chlamydia Vaccine Discovery Product CEPR(HPA) US Govt MCM Academia/Govt/NforP HPA plays a pivotal role in development of future health care interventions

7 Key Research Activities
TB Correlates of Protection Vaccines Antibiotics Toxins Botulinum Clostridium Immunotherapy Diagnostics Biosafety Detection Decontam HCAI/vCJD Training Diagnostics Technology Bio/Molecular Mening & Pertussis Correlates Vaccines Animal Models Efficacy studies Aerosol Path/ Imaging SIV Research Immune Assay NVEC Clinical Trials Assay Validation Immune Modulation Inflammation Adjuvants Emerging Diseases Virology Bacteriology SPRU Support Medical Counter Measures NIAID Anthrax Research Aligned with HPA Strategy and Programmes

8 Developing Interventions for Emerging Diseases & Bio-threat Agents
Tradition route is in vitro, then human Phase 1, 2 and then Phase 3 trials Discovery Development Licensure Pure research Translational research Traditional clinical efficacy trials not possible with diseases like Anthrax, Plague, Meliodosis, Glanders and Ebola The FDAs “Animals Rule” provides an alternative where Efficacy in 2 animal models may be accepted for licensure

9 The NIAID Programme at HPA CEPR
Anthrax in mice and NHPs (C1, D1) Plague in mice (C18) Q fever in mice (C19) Melioidosis in mice (C19) Filoviruses (C20) Anthrax in NHPs (D1) Melioidosis in NHPs (D19) Glanders in NHPs (D19) Flu (E10) Multiple agents in NHPs (D8, Dstl) Monkeypox in NHPs (D4/D7, D18, E07) GLP Antibiotics, small molecules & therapies (A1, B1) Vaccines Discovery Development Licensure Pure research Translational research

10 Animal Models: Development of New Interventions for Infectious Diseases
Development & evaluation of vaccines, therapeutics and diagnostics

11 High consequence pathogens - Surveillance and development of interventions
Easily Transmitted High mortality Limited / no treatment Approximate mortality rates Viral Hemorrhagic Fevers: Ebola Dengue (HF) Lassa fever CCHF % <20% % Bacterial infections: 1% / 20% ~40% Cutaneous Anthrax Inhalation Anthrax 5% / 90% 1% / 60% Pneumonic plague Bubonic plague Viral infections: Orthopox %

12 High Consequence Pathogen Studies
Remit: Responsible for maintaining research and development programmes concerned with viral haemorrhagic fevers and arboviruses in line with the department’s capacity as a HPA reference centre and WHO collaborating centre for virus research and reference. Reduce the impact of new and re-emerging health threats and help manage UK health protection emergencies through effective early detection and response.

13 Special Pathogens Reference Unit
Virus Reference service: Flaviviridae Bunyaviridae Togaviridae Reoviridae Arboviruses “To reduce the impact of new and re-emerging threats and manage UK health protection emergencies through effective early detection and response” Virus research programme provides ready to action relevant skills and knowledge capacity to rapidly respond to new virus threats (c.f. expertise of virology staff to pandemic flu activities) Haemorrhagic Fever viruses Filoviridae Arenaviridae Others “Work on high consequence pathogens through WHO international collaborations to build preparedness to infectious disease threats” Orthopoxvirus Hantavirus Henipaviruses

14 Understanding viruses
Current virology projects Outputs: Programme built around GIA Assay development / validation Direct patient monitoring Assay roll out to global partners Underpinning Knowledge Training & Knowledge transfer Work at high containment (CL4) Scientific reputation Travel advice GIA Arbo / VHF Georgia SC DTRA / UK NIAID Filovirus reagents DTRA Ebola model Euro-P4 FP7 Epidemiology Kazakhstan Japan-P4 Kyrgyzstan UK - CPAC ArboZ-net Surveillance Understanding viruses Infrastructure “To reduce the impact of new and re-emerging threats and manage UK health protection emergencies through effective early detection and response” “Strengthening public health capacity re better diagnostics and response” “Building similar capacities in partner / collaborating countries leading to better preparedness to new and re-emerging threats”

15 Translational Research Activities
Product Research Development Clinical C.difficile TB Therapeutics Sepsis MCM Chlamydia Meningitis Pertussis Vaccines MCM TB Emerging Dis Influenza MCM Pathogens HCAI Diagnostics Diagnostics vCJD Blood Emerging Dis Radiation

16 The Centre for Emergency Preparedness and Response
Miles Carroll Deputy Director Head of Research

17 Understanding Pathogenesis and Disease Kinetics: H1N1
This is a really nice slide. Points to make: Kinetics of viral load correlate with dose as expected Nasal wash is a good method to analyse upper respiratory involvement Peak rises quickly and reduces quickly in an earlier time frame than the progression of clinical disease Nasal wash - viral load TCID50 Developed for Evaluation of swine flu vaccines

18 Influenza Animal Models: How Realistic Are They?
Natural infection - dose ≈ 0.6 – 3.0 pfu Ferret model – dose = 106 pfu I start with the animal dose here and then move to the human situation with an obviously much reduced dose. – One of the questions I had in London last week was asking about natural routes of transmission in humans and whether it was direct via droplets or fomites. Continue by posing the hypothesis that a lower dose would still give rise to similar infection in the model Human disease kinetics:incubation period 2-7 days for H1N1. Would lower dose effect disease kinetics and pathogenesis? Increased sensitivity for evaluation of vaccines and therapeutics 18

Download ppt "3rd September 2010 INSERM, Lyon"

Similar presentations

Responding to the Threat of Bioterrorism: A Status Report on Vaccine Research in the United States Good Morning. Over the next 1 ½ hours of so I’ll be.

Responding to the Threat of Bioterrorism: A Status Report on Vaccine Research in the United States Good Morning. Over the next 1 ½ hours of so I’ll be.
MINISTRY OF HEALTH ACTION PLAN FOR THE PREVENTION AND CONTROL OF ANTHRAX Dr. Marion BullockDuCasse, SMO(H) Director, Emergency, Disaster Management and.

MINISTRY OF HEALTH ACTION PLAN FOR THE PREVENTION AND CONTROL OF ANTHRAX Dr. Marion BullockDuCasse, SMO(H) Director, Emergency, Disaster Management and.
Highly containment laboratory in the National Institute of Infectious Diseases, Tokyo, Japan: activities, circumstances, and future challenges Masayuki.

Highly containment laboratory in the National Institute of Infectious Diseases, Tokyo, Japan: activities, circumstances, and future challenges Masayuki.
Challenges of the 2009 H1N1 Pandemic Influenza: Charles Penn Global Influenza Programme World Health Organization Geneva.

Challenges of the 2009 H1N1 Pandemic Influenza: Charles Penn Global Influenza Programme World Health Organization Geneva.
1 Institute of Epidemiology and Infectious Diseases Research Activities The L.V. Gromashevsky Institute of Epidemiology and Infectious Diseases Svetlana.

1 Institute of Epidemiology and Infectious Diseases Research Activities The L.V. Gromashevsky Institute of Epidemiology and Infectious Diseases Svetlana.
Center for Biologics Evaluation and Research Applying Regulatory Science to Advance Development of Innovative, Safe and Effective Biologic Products Carolyn.

Center for Biologics Evaluation and Research Applying Regulatory Science to Advance Development of Innovative, Safe and Effective Biologic Products Carolyn.
Overview of Terrorism Research at the CDC Dixie E. Snider, M.D., MPH. Associate Director for Science Presented at 2003 Medical Research Summit March 6,

Overview of Terrorism Research at the CDC Dixie E. Snider, M.D., MPH. Associate Director for Science Presented at 2003 Medical Research Summit March 6,
Center for Biologics Evaluation and Research FDA Overview Site Visit Carolyn A. Wilson, Ph.D. Associate Director for Research.

Center for Biologics Evaluation and Research FDA Overview Site Visit Carolyn A. Wilson, Ph.D. Associate Director for Research.
Prevention and control of communicable disease. Over the last century, infectious diseases have lost a lot of their threat to individuals’ health as well.

Prevention and control of communicable disease. Over the last century, infectious diseases have lost a lot of their threat to individuals’ health as well.
Keeping Europe healthy

Keeping Europe healthy
Pandemic Influenza Preparedness Kentucky Department for Public Health Department for Public Health.

Pandemic Influenza Preparedness Kentucky Department for Public Health Department for Public Health.
Biosafety and the Southeast Asian Clinical Infectious Diseases Network (SEAICRN) Rogier van Doorn Clinical Microbiologist Wellcome Trust Major Overseas.

Biosafety and the Southeast Asian Clinical Infectious Diseases Network (SEAICRN) Rogier van Doorn Clinical Microbiologist Wellcome Trust Major Overseas.
Infections of the GI Tract November 19, 2007 NCDD Meeting Chair: Mitchell B. Cohen, MD Vice Chair: Richard S. Blumberg, MD.

Infections of the GI Tract November 19, 2007 NCDD Meeting Chair: Mitchell B. Cohen, MD Vice Chair: Richard S. Blumberg, MD.
Emerging Diseases – Ready and Waiting Aileen J Plant Curtin University of Technology 19 October, 2004 Emerging Diseases: the human health perspective.

Emerging Diseases – Ready and Waiting Aileen J Plant Curtin University of Technology 19 October, 2004 Emerging Diseases: the human health perspective.
NIAID Commitment to Influenza Research and Preparedness F. Gray Handley Associate Director for International Research Affairs National Institute of Allergy.

NIAID Commitment to Influenza Research and Preparedness F. Gray Handley Associate Director for International Research Affairs National Institute of Allergy.
Pandemic Influenza. Guidance for Pandemic Influenza: Infection Control in Hospitals and Primary Care Settings UK Pandemic Influenza Contingency Plan Operational.

Pandemic Influenza. Guidance for Pandemic Influenza: Infection Control in Hospitals and Primary Care Settings UK Pandemic Influenza Contingency Plan Operational.
Overview of the Laboratory of Respiratory and Special Pathogens Michael Schmitt, Ph.D. Chief, Laboratory of Respiratory and Special Pathogens.

Overview of the Laboratory of Respiratory and Special Pathogens Michael Schmitt, Ph.D. Chief, Laboratory of Respiratory and Special Pathogens.
Local Emergency Response to Biohazardous Incidents Dr. Elizabeth Whalen, MD Medical Director Albany County Health Department April 8, 2005 Northeast Biological.

Local Emergency Response to Biohazardous Incidents Dr. Elizabeth Whalen, MD Medical Director Albany County Health Department April 8, 2005 Northeast Biological.
Responding to SARS John Watson Health Protection Agency Communicable Disease Surveillance Centre, London.

Responding to SARS John Watson Health Protection Agency Communicable Disease Surveillance Centre, London.
Ecdc.europa.eu Tommi Asikainen, Tubingen, 22 October 2008 European Centre for Disease Prevention and Control FUTURE DISEASE CHALLENGES IN EUROPE – where.

Ecdc.europa.eu Tommi Asikainen, Tubingen, 22 October 2008 European Centre for Disease Prevention and Control FUTURE DISEASE CHALLENGES IN EUROPE – where.

Similar presentations

Ads by Google